Chinese General Practice ›› 2022, Vol. 25 ›› Issue (09): 1141-1147.DOI: 10.12114/j.issn.1007-9572.2021.02.135
• Review • Previous Articles Next Articles
Research Progress of the Prevention and Treatment of Metabolic Diseases Based on Short Chain Fatty Acids
1.The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine,Shenzhen 518033,China
2.Nanjing University of Chinese Medicine,Nanjing 210023,China
3.Shenzhen Traditional Chinese Medicine Hospital,Shenzhen 518033,China
*Corresponding author:LI Huilin,Professor,Doctoral supervisor;E-mail:sztcmlhl@163.com
Received:
2021-11-11
Revised:
2021-12-20
Published:
2022-03-20
Online:
2022-03-01
通讯作者:
李惠林
基金资助:
CLC Number:
ZENG Lin, ZHANG Pengxiang, HUANG Qian, WANG Gaoxiang, LI Huilin.
Research Progress of the Prevention and Treatment of Metabolic Diseases Based on Short Chain Fatty Acids [J]. Chinese General Practice, 2022, 25(09): 1141-1147.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2021.02.135
[1] | KIMURA I,ICHIMURA A,OHUE-KITANO R,et al. Free fatty acid receptors in health and disease[J]. Physiol Rev,2020,100(1):171-210. DOI:10.1152/physrev.00041.2018. |
[2] | KOH A,DE VADDER F,KOVATCHEVA-DATCHARY P,et al. From dietary fiber to host physiology:short-chain fatty acids as key bacterial metabolites[J]. Cell,2016,165(6):1332-1345. DOI:10.1016/j.cell.2016.05.041. |
[3] | STUMPFF F. A look at the smelly side of physiology:transport of short chain fatty acids[J]. Pflugers Arch,2018,470(4):571-598. DOI:10.1007/s00424-017-2105-9. |
[4] | SIVAPRAKASAM S,BHUTIA Y D,YANG S,et al. Short-chain fatty acid transporters:role in colonic homeostasis[J]. Compr Physiol,2017,8(1):299-314. DOI:10.1002/cphy.c170014. |
[5] | PSICHAS A,SLEETH M L,MURPHY K G,et al. The short chain fatty acid propionate stimulates GLP-1 and PYY secretion via free fatty acid receptor 2 in rodents[J]. Int J Obes:Lond,2015,39(3):424-429. DOI:10.1038/ijo.2014.153. |
[6] | NARAOKA Y,YAMAGUCHI T,HU A,et al. Short chain fatty acids upregulate adipokine production in type 2 diabetes-derived human adipocytes[J]. Acta Endocrinol (Buchar),2018,14(3):287-293. DOI:10.4183/aeb.2018.287. |
[7] | LI Z,YI C X,KATIRAEI S,et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit[J]. Gut,2018,67(7):1269-1279. DOI:10.1136/gutjnl-2017-314050. |
[8] | FROST G,SLEETH M L,SAHURI-ARISOYLU M,et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism[J]. Nat Commun,2014,5:3611. DOI:10.1038/ncomms4611. |
[9] | PERRY R J,PENG L,BARRY N A,et al. Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome[J]. Nature,2016,534(7606):213-217. DOI:10.1038/nature18309. |
[10] | KIMURA I,OZAWA K,INOUE D,et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43[J]. Nat Commun,2013,4:1829. DOI:10.1038/ncomms2852. |
[11] | LU Y Y,FAN C N,LI P,et al. Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota[J]. Sci Rep,2016,6:37589. DOI:10.1038/srep37589. |
[12] | SAMBEAT A,GULYAEVA O,DEMPERSMIER J,et al. LSD1 interacts with Zfp516 to promote UCP1 transcription and brown fat program[J]. Cell Rep,2016,15(11):2536-2549. DOI:10.1016/j.celrep.2016.05.019. |
[13] | WANG D,LIU C D,LI H F,et al. LSD1 mediates microbial metabolite butyrate-induced thermogenesis in brown and white adipose tissue[J]. Metabolism,2020,102:154011. DOI:10.1016/j.metabol.2019.154011. |
[14] | BO T B,ZHANG X Y,WEN J,et al. The microbiota-gut-brain interaction in regulating host metabolic adaptation to cold in male Brandt's voles (Lasiopodomys brandtii)[J]. Isme J,2019,13(12):3037-3053. DOI:10.1038/s41396-019-0492-y. |
[15] | KHAKISAHNEH S,ZHANG X Y,NOURI Z,et al. Gut microbiota and host thermoregulation in response to ambient temperature fluctuations[J]. mSystems,2020,5(5):e514-520. DOI:10.1128/mSystems.00514-20. |
[16] | DE GOFFAU M C,LUOPAJÄRVI K,KNIP M,et al. Fecal microbiota composition differs between children with β-cell autoimmunity and those without[J]. Diabetes,2013,62(4):1238-1244. DOI:10.2337/db12-0526. |
[17] | LI H P,CHEN X,LI M Q. Butyrate alleviates metabolic impairments and protects pancreatic β cell function in pregnant mice with obesity[J]. Int J Clin Exp Pathol,2013,6(8):1574-1584. |
[18] | LUNDH M,GALBO T,POULSEN S S,et al. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats[J]. Diabetes Obes Metab,2015,17(7):703-707. DOI:10.1111/dom.12470. |
[19] | YAMATO E. High dose of histone deacetylase inhibitors affects insulin secretory mechanism of pancreatic beta cell line[J]. Endocr Regul,2018,52(1):21-26. DOI:10.2478/enr-2018-0004. |
[20] | KHAN S,JENA G B. Protective role of sodium butyrate,a HDAC inhibitor on beta-cell proliferation,function and glucose homeostasis through modulation of p38/ERK MAPK and apoptotic pathways:study in juvenile diabetic rat[J]. Chem Biol Interact,2014,213:1-12. DOI:10.1016/j.cbi.2014.02.001. |
[21] | ELGAMAL D A,ABOU-ELGHAIT A T,ALI A Y,et al. Ultrastructure characterization of pancreatic β-cells is accompanied by modulatory effects of the HDAC inhibitor sodium butyrate on the PI3/AKT insulin signaling pathway in juvenile diabetic rats[J]. Mol Cell Endocrinol,2020,503:110700. DOI:10.1016/j.mce.2019.110700. |
[22] | GUO Y,XIAO Z,WANG Y N,et al. Sodium butyrate ameliorates streptozotocin-induced type 1 diabetes in mice by inhibiting the HMGB1 expression[J]. Front Endocrinol (Lausanne),2018,9:630. DOI:10.3389/fendo.2018.00630. |
[23] | DEN BESTEN G,BLEEKER A,GERDING A,et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation[J]. Diabetes,2015,64(7):2398-2408. DOI:10.2337/db14-1213. |
[24] | MOLLICA M P,MATTACE RASO G,CAVALIERE G,et al. Butyrate regulates liver mitochondrial function,efficiency,and dynamics in insulin-resistant obese mice[J]. Diabetes,2017,66(5):1405-1418. DOI:10.2337/db16-0924. |
[25] | TIROSH A,CALAY E S,TUNCMAN G,et al. The short-chain fatty acid propionate increases glucagon and FABP4 production,impairing insulin action in mice and humans[J]. Sci Transl Med,2019,11(489):eaav0120. DOI:10.1126/scitranslmed.aav0120. |
[26] | DE VADDER F,KOVATCHEVA-DATCHARY P,ZITOUN C,et al. Microbiota-produced succinate improves glucose homeostasis via intestinal gluconeogenesis[J]. Cell Metab,2016,24(1):151-157. DOI:10.1016/j.cmet.2016.06.013. |
[27] | DE VADDER F,KOVATCHEVA-DATCHARY P,GONCALVES D,et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits[J]. Cell,2014,156(1/2):84-96. DOI:10.1016/j.cell.2013.12.016. |
[28] | LU Y Y,FAN C N,LI P,et al. Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota[J]. Sci Rep,2016,6:37589. DOI:10.1038/srep37589. |
[29] | LI Z,YI C X,KATIRAEI S,et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit[J]. Gut,2018,67(7):1269-1279. DOI:10.1136/gutjnl-2017-314050. |
[30] | VOZZA A,PARISI G,DE LEONARDIS F,et al. UCP2 transports C4 metabolites out of mitochondria,regulating glucose and glutamine oxidation[J]. Proc Natl Acad Sci USA,2014,111(3):960-965. DOI:10.1073/pnas.1317400111. |
[31] | GAO Z G,YIN J,ZHANG J,et al. Butyrate improves insulin sensitivity and increases energy expenditure in mice[J]. Diabetes,2009,58(7):1509-1517. DOI:10.2337/db08-1637. |
[32] | HENAGAN T M,STEFANSKA B,FANG Z D,et al. Sodium butyrate epigenetically modulates high-fat diet-induced skeletal muscle mitochondrial adaptation,obesity and insulin resistance through nucleosome positioning[J]. Br J Pharmacol,2015,172(11):2782-2798. DOI:10.1111/bph.13058. |
[33] | ARAÚJO J R,TAZI A,BURLEN-DEFRANOUX O,et al. Fermentation products of commensal bacteria alter enterocyte lipid metabolism[J]. Cell Host Microbe,2020,27(3):358-375.e7. DOI:10.1016/j.chom.2020.01.028. |
[34] | GUI H B,SHEN Z M. Concentrate diet modulation of ruminal genes involved in cell proliferation and apoptosis is related to combined effects of short-chain fatty acid and pH in rumen of goats[J]. J Dairy Sci,2016,99(8):6627-6638. DOI:10.3168/jds.2015-10446. |
[35] | ZHAO J B,LIU P,WU Y,et al. Dietary fiber increases butyrate-producing bacteria and improves the growth performance of weaned piglets[J]. J Agric Food Chem,2018,66(30):7995-8004. DOI:10.1021/acs.jafc.8b02545. |
[36] | FENG Y H,WANG Y,WANG P,et al. Short-chain fatty acids manifest stimulative and protective effects on intestinal barrier function through the inhibition of NLRP3 inflammasome and autophagy[J]. Cell Physiol Biochem,2018,49(1):190-205. DOI:10.1159/000492853. |
[37] | FACHI J L,SÉCCA C,RODRIGUES P B,et al. Acetate coordinates neutrophil and ILC3 responses against C. difficile through FFAR2[J]. J Exp Med,2020,217(3):e20190489. DOI:10.1084/jem.20190489. |
[38] | DUSCHA A,GISEVIUS B,HIRSCHBERG S,et al. Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism[J]. Cell,2020,180(6):1067-1080.e16. DOI:10.1016/j.cell.2020.02.035. |
[39] | RAU M,REHMAN A,DITTRICH M,et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease[J]. United European Gastroenterol J,2018,6(10):1496-1507. DOI:10.1177/2050640618804444. |
[40] | KELLY C J,ZHENG L,CAMPBELL E L,et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function[J]. Cell Host Microbe,2015,17(5):662-671. DOI:10.1016/j.chom.2015.03.005. |
[41] | FORSLUND K,HILDEBRAND F,NIELSEN T,et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota[J]. Nature,2015,528(7581):262-266. DOI:10.1038/nature15766. |
[42] | WU H,ESTEVE E,TREMAROLI V,et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes,contributing to the therapeutic effects of the drug[J]. Nat Med,2017,23(7):850-858. DOI:10.1038/nm.4345. |
[43] | DE LA CUESTA-ZULUAGA J,MUELLER N T,CORRALES-AGUDELO V,et al. Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut[J]. Diabetes Care,2017,40(1):54-62. DOI:10.2337/dc16-1324. |
[44] | BRUNKWALL L,ORHO-MELANDER M. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes:from current human evidence to future possibilities[J]. Diabetologia,2017,60(6):943-951. DOI:10.1007/s00125-017-4278-3. |
[45] | ZHANG X,FANG Z,ZHANG C,et al. Effects of acarbose on the gut microbiota of prediabetic patients:a randomized,double-blind,controlled crossover trial[J]. Diabetes Ther,2017,8(2):293-307. DOI:10.1007/s13300-017-0226-y. |
[46] | YAN X F,FENG B,LI P C,et al. Microflora disturbance during progression of glucose intolerance and effect of sitagliptin:an animal study[J]. J Diabetes Res,2016,2016:2093171. DOI:10.1155/2016/2093171. |
[47] | WANG L,LI P,TANG Z,et al. Structural modulation of the gut microbiota and the relationship with body weight:compared evaluation of liraglutide and saxagliptin treatment[J]. Sci Rep,2016,6:33251. DOI:10.1038/srep33251. |
[48] | LIAO X Y,SONG L Y,ZENG B H,et al. Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis[J]. EBioMedicine,2019,44:665-674. DOI:10.1016/j.ebiom.2019.03.057. |
[49] | JAYACHANDRAN M,CHEN J L,CHUNG S S M,et al. A critical review on the impacts of β-glucans on gut microbiota and human health[J]. J Nutr Biochem,2018,61:101-110. DOI:10.1016/j.jnutbio.2018.06.010. |
[50] | ZHANG C,MA S,WU J,et al. A specific gut microbiota and metabolomic profiles shifts related to antidiabetic action:The similar and complementary antidiabetic properties of type 3 resistant starch from Canna edulis and metformin[J]. Pharmacol Res,2020,159:104985. DOI:10.1016/j.phrs.2020.104985. |
[51] | LIU G,LIANG L,YU G,et al. Pumpkin polysaccharide modifies the gut microbiota during alleviation of type 2 diabetes in rats[J]. Int J Biol Macromol,2018,115:711-717. DOI:10.1016/j.ijbiomac.2018.04.127. |
[52] | NIE Q,CHEN H,HU J,et al. Arabinoxylan attenuates type 2 diabetes by improvement of carbohydrate,lipid,and amino acid metabolism[J]. Mol Nutr Food Res,2018,62(20):e1800222. DOI:10.1002/mnfr.201800222. |
[53] | ZHAO C,YANG C F,LIU B,et al. Bioactive compounds from marine macroalgae and their hypoglycemic benefits[J]. Trends Food Sci Technol,2018,72:1-12. DOI:10.1016/j.tifs.2017.12.001. |
[54] | LIU Y Y,WANG C R,LI J S,et al. Phellinus linteus polysaccharide extract improves insulin resistance by regulating gut microbiota composition[J]. FASEB J,2020,34(1):1065-1078. DOI:10.1096/fj.201901943RR. |
[55] | LIU Y M,LIU W,LI J,et al. A polysaccharide extracted from Astragalus membranaceus residue improves cognitive dysfunction by altering gut microbiota in diabetic mice[J]. Carbohydr Polym,2019,205:500-512. DOI:10.1016/j.carbpol.2018.10.041. |
[56] | YAO Y,YAN L,CHEN H,et al. Cyclocarya paliurus polysaccharides alleviate type 2 diabetic symptoms by modulating gut microbiota and short-chain fatty acids[J]. Phytomedicine,2020,77:153268. DOI:10.1016/j.phymed.2020.153268. |
[57] | GU W,WANG Y,ZENG L,et al. Polysaccharides from Polygonatum kingianum improve glucose and lipid metabolism in rats fed a high fat diet[J]. Biomed Pharmacother,2020,125:109910. DOI:10.1016/j.biopha.2020.109910. |
[58] | ZHU K X,FAN H F,ZENG S J,et al. Polysaccharide from Artocarpus heterophyllus Lam.(jackfruit) pulp modulates gut microbiota composition and improves short-chain fatty acids production[J]. Food Chem,2021,364:130434. DOI:10.1016/j.foodchem.2021.130434. |
[59] | PANG B,ZHAO L H,ZHOU Q,et al. Application of berberine on treating type 2 diabetes mellitus[J]. Int J Endocrinol,2015,2015:905749. DOI:10.1155/2015/905749. |
[60] | CUI H X,ZHANG L S,LUO Y,et al. A purified anthraquinone-glycoside preparation from rhubarb ameliorates type 2 diabetes mellitus by modulating the gut microbiota and reducing inflammation[J]. Front Microbiol,2019,10:1423. DOI:10.3389/fmicb.2019.01423. |
[61] | XU X,GAO Z,YANG F,et al. Antidiabetic effects of Gegen Qinlian decoction via the gut microbiota are attributable to its key ingredient berberine[J]. Genomics Proteomics Bioinformatics,2020,18(6):721-736. DOI:10.1016/j.gpb.2019.09.007. |
[62] | XIAO S,LIU C,CHEN M,et al. Scutellariae Radix and coptidis rhizoma ameliorate glycolipid metabolism of type 2 diabetic rats by modulating gut microbiota and its metabolites[J]. Appl Microbiol Biotechnol,2020,104(1):303-317. DOI:10.1007/s00253-019-10174-w. |
[63] | TONG X L,XU J,LIAN F M,et al. Structural alteration of gut microbiota during the amelioration of human type 2 diabetes with hyperlipidemia by metformin and a traditional Chinese herbal formula:a multicenter,randomized,open label clinical trial[J]. mBio,2018,9(3):e2392-2317. DOI:10.1128/mBio.02392-17. |
[64] | CHEN M Y,LIAO Z Q,LU B Y,et al. Huang-Lian-Jie-du-decoction ameliorates hyperglycemia and insulin resistant in association with gut microbiota modulation[J]. Front Microbiol,2018,9:2380. DOI:10.3389/fmicb.2018.02380. |
[65] | WEI X Y,TAO J H,XIAO S W,et al. Xiexin Tang improves the symptom of type 2 diabetic rats by modulation of the gut microbiota[J]. Sci Rep,2018,8(1):3685. DOI:10.1038/s41598-018-22094-2. |
[66] | CAO Y,YAO G W,SHENG Y Y,et al. JinQi Jiangtang tablet regulates gut microbiota and improve insulin sensitivity in type 2 diabetes mice[J]. J Diabetes Res,2019,2019:1872134. DOI:10.1155/2019/1872134. |
[67] | LIU Y,WANG Y,NI Y Q,et al. Gut microbiome fermentation determines the efficacy of exercise for diabetes prevention[J]. Cell Metab,2020,31(1):77-91.e5. DOI:10.1016/j.cmet.2019.11.001. |
[68] | LE CHATELIER E,NIELSEN T,QIN J J,et al. Richness of human gut microbiome correlates with metabolic markers[J]. Nature,2013,500(7464):541-546. DOI:10.1038/nature12506. |
[69] | STANISLAWSKI M A,DABELEA D,LANGE L A,et al. Gut microbiota phenotypes of obesity[J]. NPJ Biofilms Microbiomes,2019,5(1):18. DOI:10.1038/s41522-019-0091-8. |
[70] | MUELLER N T,DIFFERDING M K,ZHANG M,et al. Metformin affects gut microbiome composition and function and circulating short-chain fatty acids:a randomized trial[J]. Diabetes Care,2021,44(7):1462-1471. DOI:10.2337/dc20-2257. |
[71] | HENNING S M,YANG J P,HSU M,et al. Decaffeinated green and black tea polyphenols decrease weight gain and alter microbiome populations and function in diet-induced obese mice[J]. Eur J Nutr,2018,57(8):2759-2769. DOI:10.1007/s00394-017-1542-8. |
[72] | SANG T T,GUO C J,GUO D D,et al. Suppression of obesity and inflammation by polysaccharide from sporoderm-broken spore of Ganoderma lucidum via gut microbiota regulation[J]. Carbohydr Polym,2021,256:117594. DOI:10.1016/j.carbpol.2020.117594. |
[73] | WANG K,BAO L,ZHOU N,et al. Structural modification of natural product ganomycin I leading to discovery of a α-glucosidase and HMG-CoA reductase dual inhibitor improving obesity and metabolic dysfunction in vivo[J]. J Med Chem,2018,61(8):3609-3625. DOI:10.1021/acs.jmedchem.8b00107. |
[74] | WANG L,ZENG B H,LIU Z W,et al. Green tea polyphenols modulate colonic microbiota diversity and lipid metabolism in high-fat diet treated HFA mice[J]. J Food Sci,2018,83(3):864-873. DOI:10.1111/1750-3841.14058. |
[75] | DING Y N,SONG Z H,LI H,et al. Honokiol ameliorates high-fat-diet-induced obesity of different sexes of mice by modulating the composition of the gut microbiota[J]. Front Immunol,2019,10:2800. DOI:10.3389/fimmu.2019.02800. |
[76] | LU Y Y,FAN C N,LI P,et al. Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota[J]. Sci Rep,2016,6:37589. DOI:10.1038/srep37589. |
[77] | ZHANG S M,ZHAO J W,XIE F,et al. Dietary fiber-derived short-chain fatty acids:a potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease[J]. Obes Rev,2021,22(11):e13316. DOI:10.1111/obr.13316. |
[78] | HONG Y,SHENG L L,ZHONG J,et al. Desulfovibrio vulgaris,a potent acetic acid-producing bacterium,attenuates nonalcoholic fatty liver disease in mice[J]. Gut Microbes,2021,13(1):1-20. DOI:10.1080/19490976.2021.1930874. |
[79] | QIAO S S,BAO L,WANG K,et al. Activation of a specific gut Bacteroides-folate-liver axis benefits for the alleviation of nonalcoholic hepatic steatosis[J]. Cell Rep,2020,32(6):108005. DOI:10.1016/j.celrep.2020.108005. |
[1] | WANG Xu, WEI Xu, ZHU Liguo, FENG Tianxiao, WANG Zhipeng, SHI Bin. Research Ideas of the Efficacy Mechanism and Prospect Analysis of Traditional Chinese Manipulative Therapy on Treating Spinal Degenerative Diseases with Combination of Medicine and Industry [J]. Chinese General Practice, 2023, 26(33): 4118-4124. |
[2] | XIN Gongkai, CONG Xin, YUAN Lei, CHENG Yuetong, NI Cuiping, ZHANG Weiwei, ZHANG Pingping, LIU Yu. Research Progress on Comprehensive Assessment Tools for the Elderly with Dementia [J]. Chinese General Practice, 2023, 26(33): 4103-4109. |
[3] | ZHANG Siyu, ZHOU Yuqiu, DU Xiaohui, WANG Zhengjun. Advances in Duration of Untreated Psychosis and Its Early Intervention [J]. Chinese General Practice, 2023, 26(33): 4110-4117. |
[4] | MENG Jiangtao, YANG Siyu, SUN Lei, LEI Ruining, ZHAO Xiaoxia. Advances in the Prognostic Value of Diffusion Tensor Imaging with Motor Evoked Potential for Motor Function in Cerebral Infarction Patients with Hemiplegia [J]. Chinese General Practice, 2023, 26(32): 4098-4102. |
[5] | WANG Jiaxin, ZHAO Yali. Domestic and International Assessment Tools for Medical Teamwork: a Systematic Review [J]. Chinese General Practice, 2023, 26(31): 3951-3962. |
[6] | WEI Mengyu, WANG Jiajia, ZHANG Yingying, LI Chunyang, LI Jiansheng. Research Status of Patient-reported Outcome Assessment Tools for Obstructive Sleep Apnea [J]. Chinese General Practice, 2023, 26(30): 3725-3733. |
[7] | XIAO Yuqian, BAI Yanjie, WANG Yan, CHEN Shuying, CHEN Limin, SUN Kexin, WAN Jun. Research Progress of Mitochondrial Transfer in Post-stroke Cognitive Impairment [J]. Chinese General Practice, 2023, 26(30): 3833-3840. |
[8] | YUAN Xiwei, NAN Yuemin. Research Progress of Structure, Function and Mechanism of Action of Mitofusin 2 in Liver Diseases [J]. Chinese General Practice, 2023, 26(30): 3841-3846. |
[9] | ZHANG Zhendong, CAI Bin, WANG Hongwei, QIAO Zengyong. Study on the Changes of Intestinal Flora and Its Metabolite Phenylacetylglutamine in Patients with Chronic Heart Failure [J]. Chinese General Practice, 2023, 26(29): 3665-3673. |
[10] | LIU Yu, YUE Ting, YANG Dongyu, ZHAO Zhongting, YANG Jibo, ZHU Tiantian. Research Progress on Mechanism of Autophagy in the Pathogenesis of Rheumatoid Arthritis [J]. Chinese General Practice, 2023, 26(29): 3710-3714. |
[11] | PU Yu, ZHANG Jixiang, DONG Weiguo. Advances in Ferroptosis and Inflammatory Bowel Disease [J]. Chinese General Practice, 2023, 26(29): 3698-3703. |
[12] | XIAO Liqi, YANG Li, CUI Saixian, ZHANG Yayuan, WANG Yulu, HE Yan. Advances in the Association of High Salt-induced Gut Microbiota Disturbances with Salt-sensitive Blood Pressure [J]. Chinese General Practice, 2023, 26(29): 3704-3709. |
[13] | REN Yanfeng, LIU Shimeng, TAO Ying, CHEN Yingyao. A Systematic Review of Medication Preferences for Patients with Depression Based on Discrete Choice Experiment and Best-worst Scaling [J]. Chinese General Practice, 2023, 26(28): 3559-3564. |
[14] | TANG Shilan, XIE Kexin, LIU Lingyu, QI Tiantian, YANG Yansui. Advances in Rehabilitation Outcomes and Care in Patients with Prolonged Disorders of Consciousness [J]. Chinese General Practice, 2023, 26(27): 3342-3348. |
[15] | LIANG Xuemei, WANG Rui, ZHAO Yuhuan, XU Tianjiao, WANG Wei, SUN Weidong. Transcranial Low-level Laser Therapy: a Novel Treatment for Depression [J]. Chinese General Practice, 2023, 26(27): 3335-3341. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||